The AllTrials Campaign: Achievements, Advocacy, and Ongoing Gaps

Origins of the AllTrials Movement

The AllTrials campaign was launched in January 2013 by a coalition of advocacy groups and scientific leaders including Sense About Science, the BMJ, the Cochrane Collaboration, and Ben Goldacre. Its core message was simple yet bold: “All trials registered. All results reported.” This call to action was directed toward pharmaceutical companies, regulatory authorities, universities, and journals that were collectively responsible for a long-standing issue in biomedical research—non-disclosure of trial results.

Before the campaign, many clinical trials, especially those with negative or neutral outcomes, remained unpublished. This publication bias skewed the evidence base used by doctors, patients, and policymakers. AllTrials aimed to fix that by demanding mandatory trial registration and public result reporting for all clinical studies—past, present, and future.

Core Objectives and Methods of Advocacy

At its core, AllTrials sought to rectify a major ethical and scientific problem: the suppression of clinical trial data. Its objectives included:

• Universal registration of all trials before the first subject is enrolled
• Public availability of trial protocols and results in a timely fashion
• Inclusion of legacy trials in disclosure mandates
• Development of policy frameworks that would legally enforce transparency

The campaign used public petitions, press releases, policy lobbying, academic partnerships, and watchdog tools such as TrialsTracker to pressure non-compliant entities. Over 750 organizations, including major academic institutions, charities, and patient groups, endorsed the AllTrials initiative.

Impact on Global Clinical Trial Reporting Standards

One of the most profound successes of the campaign was its influence on global transparency legislation and sponsor practices. While correlation does not imply causation, the following events followed the surge in AllTrials advocacy:

• The EMA introduced Policy 0070 to make clinical data publicly available
• The EU Clinical Trial Regulation 536/2014 mandated result posting on EudraCT
• The FDA Amendments Act (FDAAA) Final Rule in the U.S. began enforcement in 2017
• ClinicalTrials.gov and WHO ICTRP saw significant upticks in trial postings

Furthermore, major pharmaceutical sponsors like GSK, Johnson & Johnson, and Roche initiated voluntary public trial result portals, inspired in part by public and regulatory pressure amplified by AllTrials.

Academic Shifts and Journal Policy Alignment

Academic journals responded to the movement by tightening their requirements. The ICMJE reaffirmed its stance on mandatory trial registration, and leading journals such as The BMJ, PLOS Medicine, and The Lancet supported retrospective disclosures of missing results. Universities began requiring investigators to post results as a condition of grant renewals or tenure promotion.

Transparency Tools and Monitoring Mechanisms

To maintain momentum, developers and researchers launched digital tracking tools that publicly shamed non-compliant sponsors and institutions. Tools like the FDAAA Trials Tracker from the University of Oxford provided real-time data on trial result submission rates. These platforms monitored sponsors’ performance and highlighted areas where compliance was lagging.

Such initiatives brought greater public scrutiny and media coverage to institutions failing to meet basic transparency expectations. Reports and dashboards ranked companies by compliance percentages and deadlines, creating incentives for reform.

Challenges and Criticisms Faced by the AllTrials Campaign

Despite success, AllTrials faced several roadblocks:

• Retrospective Reporting: Many older trials remain undisclosed, and no universal mechanism exists to mandate their publication.
• Variable Global Policies: Discrepancies across registries such as ClinicalTrials.gov, EudraCT, and Japan’s JPRN hinder unified compliance.
• Enforcement Limitations: Few sponsors face actual penalties for non-compliance.
• Academic Gaps: Investigator-led trials often fall through the cracks due to lack of oversight or awareness.

Moreover, despite support from large sponsors, the campaign struggled to gain momentum in lower- and middle-income countries due to resource constraints and weak infrastructure.

Ethical Relevance and Regulatory Oversight

The ethical implications of undisclosed trials are substantial. Patients who participate in research do so with the belief that their contribution will benefit future healthcare decisions. Non-disclosure betrays this trust and leads to wasteful duplication of research. Regulatory authorities like the FDA, EMA, and WHO have all issued guidelines emphasizing the importance of timely trial reporting, yet implementation varies by region.

According to a WHO joint statement, all trials should be registered and their results reported within 12 months of study completion—a goal still unmet globally. WHO’s position paper on disclosure practices has reinforced AllTrials’ advocacy at a policy level. (See WHO Publications).

Legacy and the Way Forward

The AllTrials campaign catalyzed a new era of clinical research ethics and data sharing. While gaps persist, it elevated transparency to a global priority and reshaped stakeholder behavior. Today, regulatory teams and sponsors rely on established SOPs, validation templates, and audit tools to stay compliant. Platforms like PharmaSOP.in offer implementation guides that institutionalize disclosure workflows.

Going forward, greater automation, registry harmonization, and public accountability will be key. Institutional Review Boards (IRBs), funders, and journals must continue to pressure lagging institutions until transparency becomes standard operating procedure worldwide.

Conclusion

The AllTrials campaign marked a turning point in clinical trial history. It transformed hidden results into a public debate, empowered patients and researchers alike, and improved ethical norms across the pharmaceutical industry. Yet, full transparency is still a work in progress. Continued collaboration between regulatory bodies, sponsors, ethics committees, and advocacy groups will be essential to realize the vision of complete, accessible, and trustworthy clinical trial data for all.

The AllTrials Campaign: Evolution, Impact, and Barriers

Introduction to the AllTrials Campaign

The AllTrials Campaign was launched in 2013 as a global movement to demand that all clinical trials—past and present—be registered and have their results reported. Initiated by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, the campaign quickly gained international traction and has since reshaped conversations around clinical transparency, ethics, and accountability in medical research.

The campaign’s motto, “All Trials Registered. All Results Reported.”, has become a rallying cry for researchers, regulatory bodies, journals, and patient advocacy groups. The underlying concern is simple yet urgent: missing clinical trial results distort the evidence base used by clinicians, regulators, and policymakers to make decisions about patient care.

Founding Organizations and Strategic Goals

The AllTrials campaign is driven by several well-respected organizations. Cochrane’s data-driven research approach, BMJ’s editorial stance, and the statistical scrutiny promoted by Goldacre’s initiatives have created a compelling synergy. The core objectives of the campaign include:

• Mandating public registration of all clinical trials at inception
• Ensuring timely disclosure of trial results, regardless of outcome
• Retrospective disclosure of older, unpublished trials
• Policy change at institutional, national, and international levels

Over time, the campaign has helped push forward policy reform and sponsor accountability. For example, many institutions now require ClinicalTrials.gov or EudraCT registration as a condition for IRB approval or journal publication.

Successes Achieved Through Advocacy and Policy Reform

Since its inception, AllTrials has garnered support from over 750 organizations worldwide, including universities, research sponsors, regulators, and patient groups. The campaign has led to tangible policy changes:

• The European Medicines Agency (EMA) launched a database to make clinical data publicly accessible.
• The U.S. Final Rule (FDAAA 801) clarified disclosure expectations and timelines.
• WHO’s Joint Statement echoed many of AllTrials’ demands for transparency.
• The UK Health Research Authority issued mandates to enforce trial result reporting.

These achievements mark a significant shift toward transparency becoming an expected, if not legally enforceable, norm. Tools like the FDAAA Trials Tracker help monitor sponsor compliance in real time.

Public Engagement and the Power of the Petition

One of the campaign’s most compelling tools was the public petition, which gathered over 90,000 signatures in its early years. This grassroots momentum added pressure on pharmaceutical companies and research institutions to commit publicly to transparency.

Major players like GSK and Johnson & Johnson acknowledged the movement, with GSK stating its commitment to post all results on its public register. Such corporate statements were seen as milestones in voluntary disclosure adoption by industry giants.

Integration with Broader Movements and Academic Research

AllTrials is closely aligned with the broader Open Science movement, which advocates for data sharing, reproducibility, and equitable access to research outputs. In academia, journals increasingly require trial registration as a precondition for publishing results, following guidelines by ICMJE and CONSORT.

Independent academic assessments have also validated the campaign’s impact. A 2020 study in PLOS Medicine showed significant improvements in results disclosure rates among large academic sponsors post-AllTrials. However, smaller institutions and investigator-initiated studies still lag behind.

Challenges: Enforcement, Monitoring, and Legacy Data

Despite the momentum, several challenges persist:

• Lack of enforcement for retrospective trials—especially pre-2007 data
• Inconsistent registry use outside of high-income countries
• Resource constraints at investigator-initiated research sites
• Limited punitive mechanisms for non-compliance

Furthermore, while some regulators have built trial data portals, interoperability and public usability vary significantly. For instance, the EU CTR and ClinicalTrials.gov differ in how they present and access summary results. Organizations like ClinicalStudies.in now play a role in bridging knowledge and training gaps for research teams globally.

Conclusion and Future Directions

The AllTrials campaign succeeded in raising global awareness about hidden data in clinical research and catalyzed regulatory and ethical reform. However, its work is far from complete. Strengthening enforcement, addressing non-reporting in low-resource settings, and ensuring accessibility of legacy data remain high-priority issues.

Transparency isn’t just a compliance box—it is a foundational pillar of good science and public trust. Sponsors, CROs, academic institutions, and regulatory bodies must continue to collaborate, ensuring that the vision of AllTrials—All Trials Registered. All Results Reported.—becomes a reality for all clinical research stakeholders.

For a deeper dive into global registry tools, visit EMA’s registry platform or access training resources on protocol transparency at PharmaValidation.in.

Ensuring Ethical Publication of Clinical Trials Through GPP Guidelines

Introduction to GPP: Why Ethical Publication Matters

Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these concerns, the International Society for Medical Publication Professionals (ISMPP) developed the Good Publication Practice (GPP) guidelines, currently in its third version (GPP3).

These guidelines aim to promote transparency, responsible authorship, and ethical sponsor engagement in the publication of clinical trial data. GPP applies to pharmaceutical companies, contract research organizations (CROs), academic collaborators, and medical writers involved in the publication planning and dissemination process.

Core Principles of GPP3

GPP3 outlines the ethical standards and operational expectations for preparing and publishing trial-related manuscripts. Core principles include:

• Transparency: Disclose sponsor involvement, funding sources, and data access rights clearly.
• Accountability: Ensure all listed authors meet the ICMJE authorship criteria.
• Accuracy: Report trial results honestly, without bias, spin, or data manipulation.
• Timeliness: Publish results in a timely manner consistent with regulatory disclosure timelines.
• Respect for contributors: Acknowledge the roles of statisticians, writers, and investigators.

These standards align with ICMJE’s Uniform Requirements and complement regulatory requirements from FDA, EMA, and WHO registries.

Authorship Ethics: Avoiding Misconduct

One of the most critical elements in ethical publishing is defining who qualifies as an author. According to both GPP and ICMJE guidelines, authors must meet all of the following criteria:

• Substantial contribution to study design, data analysis, or interpretation
• Drafting or revising the article critically for intellectual content
• Approval of the final version for publication
• Accountability for the accuracy and integrity of the published content

GPP3 strongly discourages ghostwriting—where individuals contribute without acknowledgment—or guest authorship—where individuals are credited without meaningful contribution. Both practices are considered publication misconduct.

Managing Sponsor Involvement and Independence

Sponsors often fund and manage trials, but their role in publication must be disclosed and regulated. Ethical sponsor practices include:

• Allowing authors full access to data or summary-level analyses
• Refraining from controlling the publication’s message or conclusions
• Disclosing conflicts of interest (COIs) related to employment, funding, or stock ownership
• Ensuring transparency about editorial assistance from medical writers

Example: In a multi-site trial on a novel anticoagulant, the sponsor may support writing through an external medical communication agency. However, all authors should approve the content, and the writer’s name and funding source must be disclosed.

Publication Planning and Documentation

Ethical publication also involves organized planning. GPP3 recommends sponsors and authors collaboratively develop a publication plan that includes:

• A publication timeline linked to trial milestones (e.g., database lock, CSR finalization)
• A list of planned abstracts, posters, and manuscripts
• Defined roles and responsibilities for each author and contributor
• A process for conflict resolution and content approval

Publication plans help avoid publication bias by documenting the intent to publish all prespecified outcomes, regardless of result significance. Many sponsors now maintain internal SOPs to govern these workflows.

External Guidelines Complementing GPP

GPP guidelines work in tandem with several other international frameworks:

• EU CTR: Requires summary results and layperson summaries within 12 months of trial completion
• FDAAA 801: Mandates results reporting on ClinicalTrials.gov
• ICMJE: Sets criteria for authorship and trial registration
• WHO ICTRP: Advocates for global result disclosure standards

GPP-compliant sponsors should ensure their practices do not contradict these overlapping obligations.

Role of Medical Writers and Review Committees

Medical writers play an integral role in transforming complex trial data into clear, accurate, and ethical publications. GPP encourages acknowledgment of their work and insists on:

• Documentation of writing contributions in the manuscript or submission form
• Verification that writers had no role in data manipulation or outcome shaping
• Confirmation that writers received direction from authors, not solely from the sponsor

Meanwhile, publication review committees (PRCs) at many organizations ensure that all manuscripts meet internal quality standards and GPP principles before journal submission.

Common Violations and Their Consequences

GPP violations can lead to severe reputational and regulatory consequences. Common violations include:

• Failing to disclose sponsor involvement
• Publishing only favorable outcomes (publication bias)
• Suppressing trial data or delaying negative result publication
• Adding honorary or ghost authors
• Not declaring writer contributions or financial support

Example: In a 2020 audit of 75 industry-sponsored trials published in top journals, over 20% failed to disclose medical writing support—despite involvement. Journals like The Lancet and BMJ have since tightened disclosure policies.

Conclusion: Making GPP a Standard Practice

The GPP guidelines represent a foundational framework for ethical trial result publication. Implementing GPP practices not only ensures compliance but fosters trust among peers, regulators, patients, and the public. Sponsors, CROs, and academic institutions should integrate GPP into their publication SOPs, training, and governance systems.

As clinical trial disclosure becomes increasingly regulated, ethical publication isn’t just a best practice—it’s a moral, scientific, and legal imperative. Upholding GPP principles safeguards the value of medical research and protects the patients whose participation makes it possible.

Understanding Global Regulations Governing Clinical Trial Transparency

Introduction to Trial Disclosure: Why It Matters

Transparency in clinical trials is not just a regulatory obligation—it’s an ethical imperative. The timely registration of trials and public reporting of results prevent selective reporting, publication bias, and unethical trial duplication. It also reinforces patient trust and supports future research.

Major global initiatives such as the WHO ICTRP have unified various registries and mandates under a broader transparency umbrella. These frameworks aim to ensure that all trials—regardless of outcome—are publicly visible from initiation through results publication.

FDAAA 801: U.S. Disclosure Obligations

In the United States, the Food and Drug Administration Amendments Act of 2007 (FDAAA 801) mandates the registration and results reporting of applicable clinical trials (ACTs) on ClinicalTrials.gov. These include most interventional studies of FDA-regulated drugs, biologics, and devices.

Key requirements include:

• Registration within 21 days of enrolling the first participant
• Results submission within 12 months of the primary completion date
• Posting of summary results and adverse event data

Non-compliance can result in daily fines of up to $13,000 and withholding of NIH grant funding.

EU Clinical Trials Regulation (EU CTR)

Under Regulation (EU) No. 536/2014, the European Union implemented a harmonized system for clinical trial authorization, registration, and disclosure via the Clinical Trials Information System (CTIS). Key distinctions from FDAAA include:

• Mandatory registration before the trial begins
• Results submission within 12 months of trial completion
• Layperson summaries required alongside technical results
• Full protocol transparency upon trial completion

Unlike ClinicalTrials.gov, CTIS supports public access to documents like the investigator brochure and protocol synopsis.

Role of WHO ICTRP and Global Registries

The World Health Organization’s International Clinical Trials Registry Platform (ICTRP) aggregates data from over 20 primary registries worldwide. This includes:

• CTRI (India)
• ISRCTN (UK)
• ANZCTR (Australia/New Zealand)
• JPRN (Japan)

WHO mandates 20-item minimum dataset registration and prospective trial entry. Many regulatory bodies and journals align with WHO standards to ensure global compliance.

ICMJE and Academic Journal Requirements

The International Committee of Medical Journal Editors (ICMJE) requires prospective trial registration as a condition for manuscript consideration. Acceptable registries must be publicly accessible and approved by WHO.

This requirement, while not regulatory, has a massive impact on research visibility. Unregistered studies may face publication rejection, diminishing their scientific contribution and ethical integrity.

National-Specific Regulations: A Snapshot

Consequences of Non-Compliance

Failure to comply with disclosure rules has serious implications. Sponsors may face financial penalties, reputational damage, or legal action. In 2021, the FDA issued Notice of Noncompliance letters to major institutions, highlighting the shift toward aggressive enforcement.

Moreover, funding agencies like NIH and Wellcome Trust now require strict adherence to trial transparency guidelines. Non-compliant institutions risk losing grant eligibility, jeopardizing future research.

Enforcement Trends and Global Harmonization

Regulatory bodies are increasingly focusing on harmonization of trial transparency. The EU-US “Transatlantic Dialogue” and WHO’s efforts to standardize data across registries signify a future of unified disclosure protocols.

Recent policy shifts include integration of patient lay summaries, structured datasets (like the TRDS format), and linked open data systems. These developments aim to enhance machine readability and public accessibility of trial data.

Summary and Future Outlook

The global landscape of clinical trial disclosure is evolving rapidly. Organizations must adapt to an increasingly regulated environment by implementing robust disclosure workflows, investing in compliance systems, and training cross-functional teams.

As trial transparency expectations grow, success will depend on proactive strategies, clear documentation, and ethical commitments to participant rights and data integrity.